AC
IBRX icon

Armistice Capital’s ImmunityBio IBRX Stock Holding History

Armistice Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,764,000
Closed -$20.5M – 360
2025
Q2 		$20.5M Buy
+7,764,000
New +$20.9M 0.35% 45
2023
Q4 		– Sell
-3,476,000
Closed -$5.87M – 329
2023
Q3 		$5.87M Buy
+3,476,000
New +$6.98M 0.09% 108
2023
Q2 		– Sell
-5,795,927
Closed -$10.5M – 250
2023
Q1 		$10.5M Buy
+5,795,927
New +$18M 0.15% 89

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Armistice Capital's IBRX Position: Q3 2025 in Review

Armistice Capital sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 7,764,000 shares — an estimated $20.5M sold.

Armistice Capital first reported a position in IBRX in Q1 2023 and held it in 3 quarters. The position peaked at $20.5M in Q2 2025. 264 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

  • Armistice Capital reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
  • Armistice Capital sold 7,764,000 ImmunityBio shares in Q3 2025, an estimated $20.5M.
  • Armistice Capital first reported a position in ImmunityBio in Q1 2023 and held it in 3 quarters.
  • Armistice Capital's ImmunityBio position peaked at $20.5M in Q2 2025.
  • 264 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.